Together, these results suggest that the characterization of E‐cadherin/β‐catenin/CD61 expression in tumors and the drug effect of tumoroids could serve as powerful strategies for evaluating the therapeutic responses and developing potential treatment modalities for CRC precision medicine.[82]. Here, ITGB3 is linked to colorectal carcinoma.